Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week randomized double-blind study of anacetrapib added to statin therapy in patients with hypercholesterolemia or low HDL-C
KCT0000937Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia and Hypo-HDL cholesterolemia (HALP) comparing Anacetrapib + statin with Placebo + statin (2 arms). Started Jun 2013; status: recruiting.
02
Drugs
anacetrapib
03
Conditions
hypercholesterolemiaHypo-HDL cholesterolemia (HALP)
Beyond the preview
Go deeper on KCT0000937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000937.